Juluca

Dolutegravir sodium and rilpivirine hydrochloride, the active ingredients in Juluca, are an integrase strand transfer inhibitor and a non‑nucleoside reverse transcriptase inhibitor presented as a 50 mg/25 mg oral tablet for oral use. It is used for maintenance therapy of HIV‑1 infection in adults with virologically suppressed viral load. GNH USA supplies Juluca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Juluca is indicated for HIV‑1 infection and is used as part of antiretroviral therapy to maintain viral suppression. - HIV‑1 infection (maintenance): Maintains virologic suppression in adults with HIV‑1 RNA < 50 copies/mL on a stable regimen. - Combination antiretroviral therapy: Provides a two‑drug oral option when used with other antiretrovirals to sustain viral load control. - Virologically suppressed patients: Offers a simplified regimen for adults who have achieved stable viral suppression.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Nausea: occasional, may improve with food. - Diarrhea: watery stools, usually self‑limiting. - Insomnia: difficulty falling or staying asleep. - Fatigue: generalized tiredness. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Severe hypersensitivity: including fever, swelling, and difficulty breathing. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: extensive skin detachment. - Hepatotoxicity: marked elevation of liver enzymes or jaundice. - Depression or suicidal ideation: new or worsening mood changes. - Immune reconstitution inflammatory syndrome: inflammatory response after viral suppression.

Before initiating Juluca, consider the following precautions: - Pregnancy: Category B; use only if the potential benefit justifies the potential risk to the fetus. - Renal impairment: Assess renal function; dose adjustment may be required in severe impairment. - Hepatic impairment: Use with caution in patients with moderate to severe liver disease; monitor liver enzymes. - Drug resistance: Avoid in patients with known resistance to integrase inhibitors or NNRTIs. - Concomitant medications: Review all co‑administered drugs for potential interactions, especially enzyme inducers. - Store at ambient temperature: keep below 25 °C, retain in the original pack, and protect from moisture.

Juluca may interact with several medicines; monitoring is essential. Major Interactions (Avoid): - Rifampin, carbamazepine, phenytoin, or St. John's wort: strong enzyme inducers that markedly reduce dolutegravir exposure. - Antacids containing aluminum or magnesium: can lower rilpivirine absorption if taken simultaneously. Moderate Interactions (Monitor Closely): - Proton pump inhibitors (e.g., omeprazole): may decrease rilpivirine levels; separate dosing by at least 12 hours. - Certain protease inhibitors (e.g., ritonavir): may increase dolutegravir concentrations. - H2‑blockers (e.g., ranitidine): may modestly reduce rilpivirine absorption; consider timing adjustments.